ALPS Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

ALPS Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.09M	Buy	58,395 +226	+0.4%	+$3.74K	0.01%	575
2025 Q4	$767K	Buy	58,169 +27,413	+89%	+$323K	﹤0.01%	636
2025 Q3	$221K	Sell	30,756 -3,534	-10%	-$184K	﹤0.01%	1005
2025 Q2	$1.62M	Sell	34,290 -12,811	-27%	-$522K	0.01%	396
2025 Q1	$1.84M	Sell	47,101 -3,894	-8%	-$168K	0.01%	360
2024 Q4	$2.76M	Buy	50,995 +7,167	+16%	+$366K	0.02%	302
2024 Q3	$2.21M	Sell	43,828 -5,214	-11%	-$244K	0.01%	341
2024 Q2	$2.16M	Buy	49,042 +6,769	+16%	+$287K	0.01%	326
2024 Q1	$2.12M	Buy	42,273 +3,376	+9%	+$183K	0.02%	340
2023 Q4	$2.35M	Buy	+38,897	New	+$2M	0.02%	312
2022 Q4	–	Sell	-20,144	Closed	-$160K	–	1069
2022 Q3	$160K	Sell	20,144 -11,116	-36%	-$78.6K	﹤0.01%	1017
2022 Q2	$164K	Buy	+31,260	New	+$196K	﹤0.01%	1004

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ALPS Advisors's MLTX Position: Q1 2026 in Review

ALPS Advisors increased its MoonLake Immunotherapeutics (MLTX) stake by 0.39% in Q1 2026, buying an estimated $3.74K and bringing the position to 58,395 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #575.

ALPS Advisors first reported a position in MLTX in Q2 2022 and has held it in 12 quarters since. The position peaked at $2.76M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

ALPS Advisors held 58,395 shares of MoonLake Immunotherapeutics worth $1.09M as of Q1 2026.
ALPS Advisors bought 226 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $3.74K.
MoonLake Immunotherapeutics made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #575 holding.
ALPS Advisors first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 12 quarters since.
ALPS Advisors's MoonLake Immunotherapeutics position peaked at $2.76M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.